Dalvie, Neil C.
Naranjo, Christopher A.
Rodriguez-Aponte, Sergio A.
Johnston, Ryan S.
Christopher Love, J.
Funding for this research was provided by:
Bill and Melinda Gates Foundation (INV-002740)
National Cancer Institute (P30-CA14051)
Article History
Received: 17 June 2022
Accepted: 29 July 2022
First Online: 5 September 2022
Declarations
:
: Not applicable. (All yeasts consented to this study).
: Not applicable.
: N.C.D., S.A.R., and J.C.L. have filed a patent related to the RBD-L452K-F490W sequence. J.C.L. has interests in Sunflower Therapeutics PBC, Honeycomb Biotechnologies, OneCyte Biotechnologies, QuantumCyte, Amgen, and Repligen. J.C.L’s interests are reviewed and managed under MIT’s policies for potential conflicts of interest.